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AbsTrACT
background There are more than one million National 
Health Service visits in England and Wales each year for 
patients with glaucoma or ocular hypertension (OHT). 
With the ageing population and an increase in optometric 
testing, the economic burden of glaucoma- related visits is 
predicted to increase. We examined the conversion rates of 
OHT to primary open- angle glaucoma (POAG) in England 
and assessed factors associated with risk of conversion.
Methods Electronic medical records of 45 309 patients 
from five regionally different glaucoma clinics in England 
were retrospectively examined. Conversion to POAG 
from OHT was defined by deterioration in visual field 
(two consecutive tests classified as stage 1 or worse as 
per the glaucoma staging system 2). Cox proportional 
hazards models were used to examine factors (age, sex, 
treatment status and baseline intraocular pressure (IOP)) 
associated with conversion.
results The cumulative risk of conversion to POAG was 
17.5% (95% CI 15.4% to 19.6%) at 5 years. Older age 
(HR 1.35 per decade, 95% CI 1.22 to 1.50, p<0.001) was 
associated with a higher risk of conversion. IOP- lowering 
therapy (HR 0.45, 95% CI 0.35 to 0.57, p<0.001) was 
associated with a lower risk of conversion. Predicted 5- year 
conversion rates for treated and untreated groups were 
14.0% and 26.9%, respectively.
Conclusion Less than one- fifth of OHT patients managed 
in glaucoma clinics in the UK converted to POAG over a 
5- year period, suggesting many patients may require less 
intensive follow- up. Our study provides real- world evidence 
for the efficacy of current management (including IOP- 
lowering treatment) at reducing risk of conversion.
InTroduCTIon
Referral guidelines for ocular hypertension (OHT) 
or other glaucoma- related conditions in England 
currently require a repeated applanation tonom-
etry intraocular pressure (IOP) measurement of 
above 24 mm Hg if referring on IOP alone.1 Previ-
ously guidelines set the IOP threshold for referral at 
21 mm Hg and the EPIC- Norfolk study reported a 
prevalence of 10% for OHT in the English county 
of Norfolk using this IOP cut- off.2 Current guidance 
recommends that IOP- lowering eye- drops may be 
offered to patients with high IOP if they are at risk 
of visual impairment in their lifetime.1 The reported 
rate of conversion from OHT to primary open- angle 
glaucoma (POAG) is variable in the literature with, 
for example, a 5- year conversion rate of anywhere 
between 4.4% and 25%.3–6 Robust data on the like-
lihood of developing glaucoma for those with OHT 
are required to inform monitoring guidelines in terms 
of cost- effectiveness and acceptability to patients, eye 
care providers and commissioners of National Health 
Service (NHS) services.
Primary care general practitioners do not generally 
have the appropriate training or equipment for moni-
toring patients with OHT. Standard UK practice as 
such is to monitor in secondary care in hospital eye 
services (HESs). This monitoring places a strain both 
on eye care services and patients, as monitoring in 
specialist eye clinics can be inconvenient, may lead to 
‘overtreatment’ and is expensive for the NHS.2 As up 
to half of POAG is characterised as normal tension 
glaucoma in Europeans, high IOP is neither a neces-
sary nor a sufficient condition of glaucoma.2 7 There-
fore, it is likely that a proportion of patients with 
OHT are receiving unnecessarily intensive follow- up 
or treatment. With an ageing population and an 
increase in optometric testing, the number of patients 
being seen in clinics with glaucoma- related conditions 
is expected to rise, placing further strain on these 
services.8 9 Currently, there are significant glaucoma 
clinic appointment backlog issues in many ophthal-
mology departments in England and Wales.10 11
HESs in the UK are transitioning to electronic 
medical record (EMR) systems to store structured 
patient data digitally, although progress is slow.12 13 
Glaucoma clinics, in particular, have the ability to 
store structured data relevant to OHT patients such as 
IOP readings, visual field (VF) test results and which 
medications (if any) they are taking. The aims of this 
study were to use EMR data from five glaucoma 
clinics in England to retrospectively analyse what 
happens to OHT patients. The primary aim was to 
estimate the proportion of OHT cases that converted 
to POAG within 5 years and to examine factors asso-
ciated with this conversion. Our secondary objec-
tive was to consider the burden (number of unique 
scheduled appointments) that OHT patients place on 
glaucoma clinics, relative to other conditions such as 
POAG and suspected glaucoma.
MATerIAls And MeThods
Anonymised clinical data recorded between April 
2000 and March 2015 were extracted from the 
Medisoft (Medisoft, Leeds, UK) EMR at five different 
NHS Hospital Trust glaucoma clinics in England. 
Commissioned to do so by the Healthcare Quality 
Improvement Partnership as part of the National 
Clinical Audit and Patient Outcomes Programme, 
the Royal College of Ophthalmologists collected this 
data as the National Ophthalmology Database Audit 
provider.14 15 Details and summary statistics of these 
data are available elsewhere.16 The data extraction 
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Figure 1 Flow chart of patient eye selection. The flow chart also 
shows the predicted proportion of conversion for model 1 (all- cause 
survival analysis) and model 2 (stratified by treatment group).
Figure 2 A glaucoma staging system 2 (GSS2) scatterplot showing 
the eyes included for analysis. Only eyes with a baseline measurement 
in the early stages (stage 0 (green) or borderline (orange) stage, 
demarked by a red curve) were included (A). A second scatterplot 
illustrating the GSS2 stage of the last recorded follow- up visit for the 
same eyes is also shown (B). OHT, ocular hypertension; VF, visual field.
was done in November 2015. All patient data were anonymised 
and stored on a database securely held at the university.
Inclusion criteria
Figure 1 presents a flow chart for patient eye selection. With this 
EMR (Medisoft) every diagnosis entry is associated with a diagnosis 
code. As such, it is possible to search and filter for specific condi-
tions by filtering for the associated code or codes. We included 
patients with a clinical diagnosis label of OHT in at least one eye 
with no prior glaucoma- related diagnoses for either eye and with 
no significant ocular comorbidities. Specifically, eyes with a visual 
acuity (VA) of 6/18 or worse, or a diagnosis label of cataract, 
corneal pathology or eye casualty attendance were excluded. Eyes 
with age- related macular degeneration were included if they had a 
VA better than 6/18. As we are considering the risk of VF loss at a 
patient level, we are concerned with VF loss to either eye. As such, 
if both eyes were eligible, the eye with the higher baseline IOP was 
chosen for this analysis as it is potentially at a higher risk of VF 
loss. If both eyes had the same baseline IOP, one eye was chosen at 
random. For the purpose of this study, only VFs tested by using the 
Humphrey Field Analyzer (Carl Zeiss Meditec, Dublin, California, 
USA) with the 24–2, white- on- white test strategy acquired with 
the Swedish Interactive Testing Algorithm (SITA Standard or SITA 
Fast) were included in the analysis. A minimum of three reliable VF 
tests were required; one at baseline and two consecutive reliable 
examinations to enable detection of repeated VF loss if present.
To classify patients into different levels of VF damage, we used 
the glaucoma staging system 2 (GSS2) described by Brusini and 
Filacorda.17 The system classifies VF damage into one of seven 
progressively worsening categories. As we wanted to consider 
‘true’ OHT patients, we opted to only include eyes with little- 
to- no VF damage at baseline, as defined by the GSS2 (stage 0 or 
borderline stage). Baseline VF was defined as the VF closest to the 
time of diagnosis labelling, with a maximum of 1 year between the 
diagnosis and VF test. Baseline stages as measured by the GSS2 for 
all included eyes can be seen in figure 2A. The GSS2 stage at the 
last recorded follow- up visit is also shown in figure 2B.
statistical analysis
We considered follow- up VF data for up to 5 years following diag-
nosis of OHT. Any visits after this 5- year window were excluded. 
Two consecutive reliable VF exams with a GSS2 classification of 
stage 1 or worse were used to define VF loss. An unreliable VF was 
determined by the standard HFA criteria for false- positive errors 
(>15%) or fixation- loss errors (>20%). The VF with the earlier 
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Figure 3 Cox PH survival curve of 5- year conversion predictions for 
(A) all patients (green) and (B) the treated (blue) and untreated (red) 
groups with the 95% CIs. The risk table shows the number of patients 
still included in the analysis for a group over time (1- year intervals). The 
cumulative probability of conversion was higher in the untreated group 
than the treated group (p<0.01), (B). PH, proportional hazard.
Figure 4 Number of recorded patient visits for IOP measurements 
(red) and VF testing (blue) by primary diagnosis (glaucoma suspect, OHT 
and POAG) across the full- time period in the dataset. IOP, intraocular 
pressure; OHT, ocular hypertension; POAG, primary open- angle 
glaucoma; VF, visual field.
date was considered as the date of conversion. Patients with less 
than 5 years follow- up were included in the analysis but censored. 
The risk of conversion was calculated by computing the predicted 
survival function for a Cox proportional hazard (PH) model. The 
predicted survival functions were computed for a simple model 
(all- case conversion) and a model with IOP treatment as a predictor 
(figure 3).
Cox PH regression analysis was used to examine the baseline 
factors associated with incident conversion. Age, sex, baseline IOP 
(mm Hg) and treatment group (treated vs untreated) were exam-
ined both crudely and then together in a multivariable model. The 
treated group was defined as eyes that had a record of IOP- lowering 
medication, laser or surgery, while being labelled as an OHT 
patient (ie, before conversion in patients that developed POAG). 
The untreated group was defined as eyes that were recorded in 
the linked medications database but did not have any glaucoma 
medication listed and had no recorded glaucoma laser or surgery. 
To determine whether our results are affected by the choice of eye 
selected in patients with two eligible eyes, we repeated analyses 
for the fellow eye for bilaterally eligible patients instead of the 
originally included eye; results were very similar (online supple-
mentary materials).
The relative burden of OHT, POAG and glaucoma suspect 
patients on the glaucoma clinics was estimated (figure 4). This was 
defined as the relative proportion of unique clinic visits (for IOP 
or VF measurements) for each of the three clinical diagnosis labels. 
A visit for one of the labels, say OHT, was defined as a visit date 
that occurred in the range of dates while the eye of interest was 
labelled as OHT. If the diagnosis label was updated at a later date, 
for example, from OHT to POAG, then subsequent visits would 
be counted as POAG visits. A visit where both eyes had the same 
label, would be counted as one visit for that label. A visit where 
both eyes had different labels, would be counted as a visit for the 
more ‘serious’ label (where POAG >glaucoma suspect >OHT). 
The average number of months between VF tests for patients with 
at least four visits was calculated. All VF visits (including those 
with unreliable results) were included to better determine resource 
usage. All analyses were performed within the open- source statis-
tical programming environment R.18 19
resulTs
baseline characteristics
From the initial cohort of 9524 patients with a clinician diag-
nosis label of OHT, we included 3163 eyes from 3163 patients 
for our analysis (see figure 1 for inclusion flow chart). Of these, 
1716 (54%) were women, 2202 (70%) were on IOP- lowering 
treatment during their OHT diagnosis and 1531 (48%) were 
right eyes. For the included eyes, 4551/22 896 (20%) of VF 
examinations were excluded due to unreliability. Other descrip-
tive statistics can be found in table 1.
Cox Ph analysis
Survival analysis curves are shown in figure 3. Overall predicted 
conversion after 5 years was 17.5% (95% CI 15.4% to 19.6%) 
(figure 3A). When stratified by treated and untreated groups, the 
predicted conversion after 5 years was 14.0% (95% CI 11.7% 
to 16.1%) and 26.9% (95% CI 22.0% to 31.4%), respectively 
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Table 1 Statistics of included patient eyes
Included 
(n)
Median (IQr) 
age at diagnosis 
(years)
Median (IQr) 
baseline IoP 
(mm hg)
Median (IQr) 
follow- up IoP 
(mm hg)
Median (IQr) 
baseline visual 
field mean 
deviation (db)
3163 60 (51–66) 24 (20–27) 20.75 (18.33–
23.00)
−0.45 (−1.32–
0.34)
IOP, intraocular pressure.
Table 2 Results of COX PH survival univariable and multivariable 
analyses
Variable name
hr with 95% CI 
(univariable) P value
hr with 95% CI 
(multivariable) P value
Baseline age (decade) 1.36 (1.22 to 
1.51)
<0.001 1.35 (1.22 to 
1.50)
<0.001
Baseline IOP (mm Hg) 1.00 (0.97 to 
1.02)
0.70 1.00 (0.98 to 
1.03)
0.98
Sex (F) 1.07 (0.85 to 
1.35)
0.56 0.99 (0.78 to 
1.25)
0.93
Treatment (yes) 0.44 (0.35 to 
0.56)
<0.001 0.45 (0.35 to 
0.56)
<0.001
IOP, intraocular pressure; PH, proportional hazard.
(figure 3B). Of those that converted, 90% had mild or moderate 
VF loss (GSS stage 1 or Stage 2) and 10% had severe (GSS stage 
3 or Stage 4). Results of the Cox regressions (univariable and 
multivariable) are shown in table 2. Use of IOP- lowering treat-
ment was associated with a reduced chance of conversion; HR 
0.45 (95% CI 0.35 to 0.57, p<0.001). Older age was associ-
ated with an increased risk of conversion (HR 1.35 per decade, 
95% CI 1.22 to 1.50, p<0.001). There was no statistically signif-
icant association between risk of conversion and baseline IOP 
or sex.
burden on clinics
Of the total number of unique visits (recording either a VF or 
IOP measurement or both) for the three clinical labels included 
for analysis, 21% were recorded for glaucoma suspect patients, 
22% for OHT patients and 57% for POAG patients. Considering 
only VF measurements, the distribution was 23%, 23% and 54% 
for glaucoma suspects, OHT and POAG patients, respectively. 
For IOP measurements only, the distribution was 20%, 23% and 
57% (absolute numbers are shown in figure 4).
If we only consider the 3163 patients who were included in the 
survival analysis, 11 727 of 15 464 (76%) of the visits within the 
5- year study window were recorded while the eye was receiving 
IOP- lowering treatment. This corresponds to 76% and 74% of 
the IOP and VF measurements, respectively. For patients with at 
least four VF visits, the average time between VF tests was 10.9, 
9.7 and 9.6 months for glaucoma suspects, OHT patients and 
POAG patients, respectively.
dIsCussIon
This is the first study to use large- scale, real- world EMR 
data from glaucoma clinics to model conversion from OHT 
to POAG. Our survival analysis predicts that around one in 
six (17.5%) OHT patients will have detectable VF loss within 
5 years and the majority of those (67%) will have mild VF 
loss (GSS stage 1). In our study population, 70% of the 
OHT patients were receiving IOP- lowering treatment and 
these patients had a lower predicted rate of conversion of 
around one in eight (14%). This indicates that there are many 
OHT patients in the clinics, especially those who are being 
treated, that are unlikely to lose much VF function within a 
5- year window. Despite this, our data show that the average 
frequency of VF and IOP monitoring across OHT patients, 
POAG patients and glaucoma suspects is similar.
In a large multicentre clinical trial, the Ocular Hyperten-
sion Treatment Study (OHTS), the cumulative probability of 
developing POAG at 5 years was 4.4% in the treated group 
9.5% and in the untreated group.20 In another study, the 
European Glaucoma Prevention Study (EGPS), the conver-
sion rates were 13.7% and 16.4%, respectively.4 Our treated 
and untreated rates of conversion (14% and 26.9%) seem 
relatively high when compared with the above trials. There 
are several possible reasons for this discrepancy. First, we did 
not use any structure- based data (such as optic disc changes) 
for the inclusion or conversion criteria as was done in OHTS 
and EGPS, instead relying on the diagnostic labelling in the 
EMR.4 20 Second, we may be overestimating the conversion 
rate if OHT patients with perceived low risk (eg, patients with 
thick corneas) were discharged to community review without 
treatment. Finally, it is possible that OHT patients being moni-
tored in a hospital glaucoma clinic in England are a higher risk 
population than those in the studies described above, and so 
would have a higher likelihood of conversion to POAG.
Just over one in five (22%), glaucoma- related visits (OHT, 
POAG or glaucoma suspect visits) were for OHT patients. 
If only 17.5% of patients are predicted to have detectable 
VF loss within 5 years, is it necessary that they be seen in 
secondary care clinics this frequently, considering that the 
risk of significant vision loss is very low (only 1.75% of our 
study population reaching severe VF loss)? There are several 
alternative options available that would reduce the burden on 
hospitals and glaucoma clinics, such as monitoring patients in 
primary care practices or in virtual clinics. So- called ‘shared 
care’ schemes could be a possible approach for low risk 
OHT patients.8 21 22 Notably, OHT patients had VF testing 
as frequently as both POAG and glaucoma suspect patients 
further emphasising that OHT patients are using a dispropor-
tionate amount of resources, relative to the immediate risk of 
VF loss. One suggestion to reduce the burden of OHT patients 
could be to increase the follow- up period between appoint-
ments.8 Morley and Murdoch estimated that increasing time 
between follow- up visits by a factor of 1.5 could reduce the 
relative clinic workload by 30%. If the follow- up time was 
increased by a similar factor for stable, low- risk OHT patients, 
it could free up resources for high- risk or new patients.
A caveat of using this retrospective observational data is we 
cannot say for sure that the treatment caused a lower rate of 
conversion, as there may have been differential allocation of 
treatment by risk of conversion. However, it seems unlikely 
that eyes at lower risk of conversion would preferentially be 
given treatment. Another limitation of our approach is that 
we did not have data regarding other potential risk factors for 
conversion, such as family history, central corneal thickness 
or retinal nerve fibre defects. The OHTS reported an HR of 
0.58 (95% CI 0.44 to 0.76) of IOP medication on conver-
sion to POAG in the context of a randomised controlled trial. 
Our study illustrates the efficacy of treatment outside the 
context of a clinical trial. Age was also a significant predictor 
of conversion, both in our study and in the OHTS with our 
results being broadly in agreement with the OHTS HR of 1.22 
(95% CI 1.01 to 1.49) per decade.3 When designing the study 
protocol, one option was to consider a change of diagnosis 
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label as an outcome for conversion. However, instead we 
opted for an objective measure using VF results that did not 
rely on a clinician updating the diagnosis label in the EMR. 
We rely on initial diagnostic labels, along with VF status to 
define our population when establishing baseline status, but 
not for detection of conversion. For added robustness, we 
also required a reliable baseline VF measurement indicating 
no VF damage, as classified by the GSS2. As the dataset did 
not include any objective structural data, this study did not 
examine OHT patients progressing to POAG in a strict clinical 
sense, but rather investigated the likelihood of developing VF 
loss in OHT patients. For the analysis on clinic burden, we 
faithfully reported visits as they appeared in the EMR and did 
not try to refine the labels based on, say, VF measurements. 
This is a minor limitation as it is possible that labels are not 
always updated as conscientiously they should be after status 
conversion.
The diagnosis labels and dates of diagnosis we used in this 
study to select OHT patients are to be interpreted as surro-
gates of disease presentation. For this analysis, we used the 
first recorded VF date as a surrogate of when the disease 
began. However, it is sometimes the case that patients come 
into a clinic previously diagnosed with OHT and already are 
being treated for some time before being entered into the 
EMR. Retrospective analyses such as ours are only possible if 
the data are accurately recorded in EMRs in a structured way. 
Today, many medical record systems are being digitised which 
makes the possibility of large, multicentre studies using ‘big- 
data’ much more feasible.12 As these data are already being 
recorded routinely, there is an opportunity of relatively cheap 
and accessible healthcare research, and patient benefit, to be 
gained from exploring them. Moreover, as these data come 
straight from clinics, it can tell us more about what goes on in 
real- world scenarios, which could inform how we organise our 
healthcare systems.
According to the National Institute for Health and Care 
Excellence glaucoma guidelines, 1.3 million people over aged 
40 in the UK have high eye pressure (above 24 mm Hg) and 
most of those who have this condition are monitored in HESs.1 
Less than one- fifth of OHT patients managed in the reported 
UK glaucoma clinics converted to POAG over a 5- year period. 
The majority of those conversions were to a mild disease stage. 
Simultaneously it is equally important to highlight results from 
those patients that were in clinics but were untreated. That 
is, more than 25% of the untreated OHT patients converted 
to POAG, although to a relatively mild disease stage within 
the time of follow- up. While it is difficult to extrapolate these 
findings to life- time risk of visual loss, since even mild disease 
can have an impact on quality of life, it is likely that these 
patients will be at an increased risk of sight- related harm during 
their lives. The results from this study highlight the issue of a 
‘one size fits all’ approach in glaucoma clinics around the UK. 
Despite many of the referrals to secondary care being deemed 
as low risk, there is often a reluctance to discharge to commu-
nity review.8 Moreover, there are several potential barriers to 
discharging patients to primary care pertaining to agreement 
on professional boundaries and responsibilities.23 Neverthe-
less, many people with OHT and without VF loss, are at a low 
risk of sight loss in the near future. Yet, according to our data, 
they take up a relatively large proportion of resources and 
are seen as frequently as POAG patients. Our results suggest 
that it would be reasonable to reduce the frequency of visits 
for OHT patients and perhaps this should be explored with 
prospective study incorporating a health economic and patient 
preference element too, echoing a need for further work that 
has been reported before.24 It would furthermore be reason-
able for such patients, who are not at risk of imminent sight 
loss, to be monitored by suitably trained and equipped opto-
metric primary care practitioners, thus reducing the burden on 
hospital secondary eye care services.
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